查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2102953

全球叢集性頭痛治療市場：策略性洞察與預測（2026-2035）

Global Cluster Headache Treatment Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球叢集性頭痛治療市場規模預計將從 2026 年的 53.1 億美元成長到 2035 年的 90.1 億美元，複合年成長率為 6.1%。

叢集性頭痛是一種罕見但極具破壞性的神經系統疾病，其特徵是反覆發作的劇烈單側頭痛，並伴隨自主神經症狀。治療策略包括旨在即時緩解疼痛的急性治療、旨在減少發作頻率的預防性治療，以及在預防性藥物生效前暫時控制症狀的過渡性治療。標靶生技藥品、醫療設備和精準神經病學的進步已經徹底改變了疾病管理，並改善了患者的長期預後。

市場促進因素

提高對該疾病的認知和早期診斷

由於醫生教育程度的提高、臨床指南的修訂以及患者意識提升的增強，頭痛診斷率有所上升，導致更多患者被轉診至頭痛專科診所。早期診斷有助於及時啟動預防性治療，擴大了可治療的患者範圍。

CGRP標靶療法的擴展

CGRP單株抗體的引入顯著拓寬了叢集性頭痛的治療選擇。這些標靶治療透過作用於參與頭痛病理生理過程的潛在神經肽通路，改善了疾病管理。

神經調控療法的廣泛應用

對於對傳統藥物反應不佳或耐受性差的患者，非侵入性神經調控設備正被廣泛接受為有效的治療選擇。攜帶式家用設備提高了治療的便利性，並有助於疾病的長期管理。

增加對罕見神經系統疾病的投資

針對罕見疾病的監管激勵措施、不斷擴大的神經學研究以及製藥業的投資增加，正在加速一系列創新叢集性頭痛治療藥物的開發和商業化。

區域趨勢

北美憑藉其先進的神經系統基礎設施、高診斷率、有利的保險報銷機制以及創新生物製藥和神經調節設備的快速普及，在全球叢集性頭痛治療市場中佔據領先地位。美國在研究、臨床試驗和商業化活動中繼續發揮主導作用。

歐洲憑藉著完善的治療指引、公共醫療體係以及實證預防療法的日益普及，維持著顯著的市場佔有率。然而，嚴格的保險報銷評估仍影響著生物製藥的推廣應用。

由於診斷技術的進步、醫療保健支出的增加、人們對罕見神經系統疾病的認知提高，以及中國、日本、韓國、印度和澳洲等國加強了專門的神經科醫療保健服務，預計亞太地區的市場成長速度最快。

在拉丁美洲、中東和非洲，隨著醫療保健的現代化，神經系統疾病的治療機會不斷改善，但在許多國家，傳統的藥物治療仍然是主要的治療方法。

本報告研究了全球叢集性頭痛治療市場，包括疾病和流行病學分析、市場影響因素、創新和研發趨勢、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析、相關法規和政策、競爭格局以及主要公司的概況。

目錄

第1章執行摘要

第2章 疾病與流行病學分析

  • 叢集性頭痛概述
    • 疾病定義
    • 疾病負擔與未滿足的需求
    • 臨床症狀和觀察
  • 疾病分類
    • 復發性叢集性頭痛
    • 慢性叢集性頭痛
  • 病因和危險因子
    • 遺傳因素
    • 神經血管機制
    • 環境因素和生活方式因素
  • 疾病的病理生理學
    • 下視丘功能障礙
    • 三叉神經自主反射的激活
    • 抑鈣素基因相關胜肽（CGRP）通路
    • 其他新型分子通路
  • 診斷和臨床評估
    • 診斷標準
    • 鑑別診斷
    • 影像檢查和診斷程序
    • 患者就診過程及診斷時間
  • 流行病學分析
    • 全球盛行率
    • 全球發病率
    • 流行病學：依疾病類型
    • 流行病學：性別
    • 流行病學：按年齡層別分類
    • 接受治療的患者群
    • 已確診患者組

第3章 市場動態

  • 市場概覽
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第4章 商業化與市場進入

  • 商業環境概述
  • 價格分析
  • 救贖方案
  • 醫療科技評估趨勢
  • 患者支持計劃
  • 市場進入的挑戰
  • 相關利益者分析

第5章：創新與通路展望

  • 創新趨勢
  • 新的治療標靶
    • CGRP路線
    • PACAP通路
    • 血清素受體靶點
    • 基於神經調控的方法
  • 管道概覽
  • 管線分析：依臨床階段分類
    • 第一階段
    • 第二階段
    • 第三階段
  • 管道分析：按作用機制分析
  • 管道分析：按模式
    • 小分子藥物
    • 單株抗體
    • 醫療設備
    • 聯合治療
  • 臨床試驗現狀

第6章 當前治療狀況

  • 目前治療模式
  • 急性治療
    • 氧氣療法
    • 曲坦
    • 其他急診護理
  • 預防性治療
    • 鈣通道阻斷劑
    • 皮質類固醇
    • CGRP單株抗體
    • 其他預防性治療
  • 神經調控療法
    • 非侵入性迷走神經刺激
    • 翼腭神經節刺激
    • 深部腦部刺激
    • 枕神經刺激
  • 治療流程
  • 未滿足的需求和未來治療趨勢

第7章 全球叢集性頭痛治療市場：規模與預測

  • 全球市場規模分析
  • 全球市場預測
  • 市場預測：按治療類型分類
  • 市場預測：依給藥途徑分類
  • 市場預測：依最終用戶分類
  • 市場預測：按分銷管道分類
  • 市場吸引力分析

第8章 全球叢集性頭痛治療市場：按細分市場分類

  • 治療類型
    • 急性治療
    • 預防性治療
    • 橋接治療
  • 藥物類別
    • 曲坦
    • CGRP單株抗體
    • 鈣通道阻斷劑
    • 皮質類固醇
    • 其他藥物類別
  • 適應症
    • 復發性叢集性頭痛
    • 慢性叢集性頭痛
  • 透過行政途徑
    • 口服
    • 注射
    • 鼻腔
  • 最終用戶
    • 醫院
    • 專科診所
    • 居家醫療
  • 透過分銷管道
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第9章 區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
    • 市場規模和成長率
    • 需求促進因素
    • 監管概述
    • 競爭優勢

第10章：主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第11章 法規與政策概述

  • 監管概述
  • 美國法律規範（FDA）
  • 歐洲法律規範（FDA）
  • 日本法律規範（FDA）
  • 印度的法律規範（FDA）
  • 中國的法律規範（NMPA）
  • 藥物核准途徑
  • 醫療設備認證流程
  • 贖回和市場進入政策
  • 新的監管趨勢

第12章 競爭格局

  • 市佔率分析
  • 競爭性標竿分析
  • 產品系列分析
  • 管道競爭力
  • 策略合作與夥伴關係
  • 授權協議
  • M&A
  • 近期趨勢

第13章：公司簡介

  • Eli Lilly and Company
  • electroCore, Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Medtronic
  • Grunenthal GmbH
  • Zosano Pharma Corp.
  • Bausch Health Companies Inc.
  • Viatris Inc.
  • Autonomic Technologies Inc.

第14章 未來展望

  • 未來市場趨勢
  • 新興技術
  • 管道商業化的前景
  • 競爭的演變
  • 投資機會
  • 情境分析
  • 長期市場預測

第15章：調查方法

簡介目錄
Product Code: KSI-008951

The Global Cluster Headache Treatment Landscape Report is expected to grow from USD 5.31 billion in 2026 at a 6.1% CAGR to USD 9.01 billion in 2035.

Cluster headache is a rare but highly debilitating neurological disorder characterized by recurrent episodes of severe unilateral headache accompanied by autonomic symptoms. Treatment strategies include acute therapies for immediate pain relief, preventive therapies that reduce attack frequency, and bridge therapies that provide temporary symptom control while preventive medications become effective. Advances in targeted biologics, device-based therapies, and precision neurology are transforming disease management and improving long-term patient outcomes.

Market Drivers

Growing Disease Awareness and Earlier Diagnosis

Improved physician education, updated clinical guidelines, and greater awareness among patients are increasing diagnosis rates and referrals to specialist headache clinics. Earlier diagnosis enables timely initiation of preventive therapies and expands the addressable treatment population.

Expansion of CGRP-Targeted Therapies

The introduction of CGRP monoclonal antibodies has significantly advanced preventive treatment options for cluster headache. These targeted therapies provide improved disease control by addressing underlying neuropeptide pathways involved in headache pathophysiology.

Increasing Adoption of Neuromodulation

Non-invasive neuromodulation devices are gaining acceptance as effective treatment options for patients with inadequate response or intolerance to conventional medications. Portable home-use devices are improving treatment convenience and supporting long-term disease management.

Rising Investment in Rare Neurological Disorders

Regulatory incentives for orphan diseases, expanding neurological research, and increased pharmaceutical investment are accelerating pipeline development and commercialization of innovative cluster headache therapies.

Market Restraints

Limited Approved Preventive Therapies

Although treatment options continue to expand, the number of approved preventive therapies remains limited, leaving substantial unmet clinical needs for many patients.

Small Patient Population

The rarity of cluster headache reduces commercial attractiveness compared with more prevalent neurological disorders and may limit investment in late-stage clinical development.

High Cost of Innovative Therapies

Biologics and advanced neuromodulation devices remain expensive, creating reimbursement challenges and limiting access in several healthcare systems.

Treatment and Technology Insights

The global cluster headache treatment market can be segmented by treatment type, drug class, indication, route of administration, end user, distribution channel, and geography.

By treatment type, the market includes acute treatment, preventive treatment, and bridge treatment. Acute therapies remain the cornerstone of disease management because patients require immediate symptom relief during attacks. Preventive therapies are experiencing the fastest growth as clinicians increasingly focus on reducing attack frequency and improving long-term disease control. Bridge therapies continue to provide temporary symptom management during initiation of preventive treatment.

By drug class, the market comprises triptans, CGRP monoclonal antibodies, calcium channel blockers, corticosteroids, and other drug classes. Triptans remain the standard acute treatment, while CGRP-targeted therapies represent the fastest-growing segment because of their targeted mechanism of action and improved preventive efficacy. Verapamil continues to serve as the most widely used preventive therapy, with corticosteroids commonly utilized as bridge treatment.

By indication, the market includes episodic cluster headache and chronic cluster headache. Episodic disease accounts for the majority of treated patients, while chronic cluster headache continues to generate significant demand for innovative preventive therapies because of its persistent disease burden.

By route of administration, treatments are available as oral, injectable, and intranasal formulations. Injectable therapies continue to play a major role because of their rapid onset during acute attacks, while oral preventive medications remain widely prescribed.

By end user, the market includes hospitals, specialty clinics, and home care settings. Specialty headache centers are increasingly adopting biologics and neuromodulation technologies, while home care continues to expand through self-administered therapies and portable treatment devices.

Technological advances including digital headache monitoring, wearable devices, artificial intelligence-assisted diagnosis, remote patient management, and neuromodulation platforms are improving disease management and supporting personalized treatment strategies.

Market Trends

The cluster headache treatment landscape continues to evolve toward personalized and mechanism-based therapies.

Key trends include:

  • Growing adoption of CGRP-targeted biologics.
  • Increasing utilization of neuromodulation technologies.
  • Expansion of specialist headache centers.
  • Rising use of home-based treatment devices.
  • Greater investment in precision neurology.
  • Improved integration of digital health and remote patient monitoring.
  • Increasing development of targeted preventive therapies.

Regional Insights

North America dominates the global cluster headache treatment market because of advanced neurological care infrastructure, high diagnosis rates, favorable reimbursement systems, and rapid adoption of innovative biologics and neuromodulation devices. The United States remains the leading contributor to research, clinical trials, and commercialization activities.

Europe maintains a significant market share through established treatment guidelines, universal healthcare systems, and increasing adoption of evidence-based preventive therapies. Careful reimbursement evaluation continues to influence biologic adoption across European countries.

Asia-Pacific is expected to register the fastest market growth owing to improving diagnosis, expanding healthcare expenditure, increasing awareness of rare neurological disorders, and strengthening specialist neurology services across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa continue to improve access to neurological care through healthcare modernization, although conventional pharmacological therapies remain the primary treatment approach in many countries.

Competitive Landscape

The cluster headache treatment market includes multinational pharmaceutical companies, biotechnology companies, medical device manufacturers, and specialty neurology developers.

Companies continue investing in CGRP monoclonal antibodies, neuromodulation devices, targeted biologics, precision medicine, and digital healthcare technologies. Strategic collaborations, licensing agreements, mergers and acquisitions, and orphan disease development programs remain important competitive strategies for strengthening market presence and accelerating innovation.

Future Outlook

The future of the cluster headache treatment market will be driven by advances in precision neurology, targeted biologics, neuromodulation technologies, and personalized medicine. Continued research into CGRP biology, neuropeptide modulation, wearable monitoring, and artificial intelligence-assisted diagnosis is expected to improve disease management and support broader adoption of innovative therapies.

Expansion of real-world evidence, digital health platforms, and patient-centered treatment approaches is expected to improve long-term outcomes while creating new commercial opportunities through 2035.

Conclusion

The global Cluster Headache Treatment Market is expected to demonstrate steady growth through 2035, supported by increasing disease awareness, expanding adoption of preventive therapies, continued innovation in CGRP-targeted biologics, and growing use of neuromodulation technologies. Although challenges related to limited approved therapies, reimbursement constraints, and the rarity of the disease remain, ongoing advances in neuroscience, precision medicine, and digital healthcare are expected to significantly improve patient outcomes and create new opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, and investors.

Key Benefits of this Report

  • Comprehensive analysis of the global cluster headache treatment market and future growth opportunities.
  • Detailed evaluation of treatment modalities, therapeutic innovations, and emerging technology trends.
  • Competitive assessment of leading companies, pipeline developments, and strategic initiatives.
  • Insights into market drivers, restraints, regulatory trends, and commercialization opportunities.
  • Valuable resource for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Market forecasting, competitive intelligence, pipeline assessment, portfolio optimization, licensing and partnership evaluation, commercialization planning, regulatory strategy development, investment analysis, and identification of emerging business opportunities.

Report Coverage

  • Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global cluster headache treatment market by treatment type, drug class, indication, route of administration, end user, distribution channel, and geography
  • Evaluation of market size, growth drivers, restraints, treatment landscape, competitive dynamics, and emerging technology trends
  • Assessment of regulatory developments, reimbursement landscape, strategic collaborations, licensing activities, mergers and acquisitions, and commercialization strategies
  • Analysis of acute therapies, preventive therapies, bridge therapies, CGRP monoclonal antibodies, neuromodulation technologies, precision neurology, and future market opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Epidemiology Highlights
  • 1.4 Commercial Landscape Overview
  • 1.5 Pipeline and Innovation Highlights
  • 1.6 Key Growth Opportunities
  • 1.7 Future Outlook

2. Disease & Epidemiology Analysis

  • 2.1 Introduction to Cluster Headache
    • 2.1.1 Disease Definition
    • 2.1.2 Disease Burden and Unmet Needs
    • 2.1.3 Clinical Presentation and Symptoms
  • 2.2 Disease Classification
    • 2.2.1 Episodic Cluster Headache
    • 2.2.2 Chronic Cluster Headache
  • 2.3 Etiology and Risk Factors
    • 2.3.1 Genetic Factors
    • 2.3.2 Neurovascular Mechanisms
    • 2.3.3 Environmental and Lifestyle Factors
  • 2.4 Disease Pathophysiology
    • 2.4.1 Hypothalamic Dysfunction
    • 2.4.2 Trigeminal Autonomic Reflex Activation
    • 2.4.3 Calcitonin Gene-Related Peptide (CGRP) Pathway
    • 2.4.4 Other Emerging Molecular Pathways
  • 2.5 Diagnosis and Clinical Assessment
    • 2.5.1 Diagnostic Criteria
    • 2.5.2 Differential Diagnosis
    • 2.5.3 Imaging and Diagnostic Procedures
    • 2.5.4 Patient Journey and Time to Diagnosis
  • 2.6 Epidemiology Analysis
    • 2.6.1 Global Prevalence
    • 2.6.2 Global Incidence
    • 2.6.3 Epidemiology by Disease Type
    • 2.6.4 Epidemiology by Gender
    • 2.6.5 Epidemiology by Age Group
    • 2.6.6 Treated Patient Population
    • 2.6.7 Diagnosed Patient Population

3. Market Dynamics

  • 3.1 Market Overview
  • 3.2 Market Drivers
    • 3.2.1 Rising Disease Awareness and Diagnosis
    • 3.2.2 Increasing Adoption of Targeted Therapies
    • 3.2.3 Advancements in Neuromodulation Technologies
  • 3.3 Market Restraints
    • 3.3.1 Underdiagnosis and Misdiagnosis
    • 3.3.2 High Treatment Costs
    • 3.3.3 Limited Availability of Approved Therapies
  • 3.4 Market Opportunities
    • 3.4.1 Expansion of CGRP-Based Therapies
    • 3.4.2 Development of Novel Neuromodulation Devices
    • 3.4.3 Emerging Markets Expansion
  • 3.5 Market Challenges
    • 3.5.1 Reimbursement Barriers
    • 3.5.2 Clinical Trial Recruitment Challenges
    • 3.5.3 Long-Term Treatment Compliance

4. Commercial & Market Access

  • 4.1 Commercial Landscape Overview
  • 4.2 Pricing Analysis
  • 4.3 Reimbursement Scenario
  • 4.4 Health Technology Assessment Trends
  • 4.5 Patient Assistance Programs
  • 4.6 Market Access Challenges
  • 4.7 Stakeholder Analysis

5. Innovation & Pipeline Landscape

  • 5.1 Innovation Trends
  • 5.2 Emerging Therapeutic Targets
    • 5.2.1 CGRP Pathway
    • 5.2.2 PACAP Pathway
    • 5.2.3 Serotonin Receptor Targets
    • 5.2.4 Neuromodulation Approaches
  • 5.3 Pipeline Landscape Overview
  • 5.4 Pipeline Analysis by Clinical Phase
    • 5.4.1 Phase I
    • 5.4.2 Phase II
    • 5.4.3 Phase III
  • 5.5 Pipeline Analysis by Mechanism of Action
  • 5.6 Pipeline Analysis by Modality
    • 5.6.1 Small Molecules
    • 5.6.2 Monoclonal Antibodies
    • 5.6.3 Medical Devices
    • 5.6.4 Combination Therapies
  • 5.7 Clinical Trial Landscape
    • 5.7.1 Ongoing Trials
    • 5.7.2 Completed Trials
    • 5.7.3 Trial Outcomes and Trends

6. Treatment Landscape

  • 6.1 Current Treatment Paradigm
  • 6.2 Acute Treatments
    • 6.2.1 Oxygen Therapy
    • 6.2.2 Triptans
    • 6.2.3 Other Acute Therapies
  • 6.3 Preventive Treatments
    • 6.3.1 Calcium Channel Blockers
    • 6.3.2 Corticosteroids
    • 6.3.3 CGRP Monoclonal Antibodies
    • 6.3.4 Other Preventive Therapies
  • 6.4 Neuromodulation Therapies
    • 6.4.1 Non-invasive Vagus Nerve Stimulation
    • 6.4.2 Sphenopalatine Ganglion Stimulation
    • 6.4.3 Deep Brain Stimulation
    • 6.4.4 Occipital Nerve Stimulation
  • 6.5 Treatment Algorithm
  • 6.6 Unmet Needs and Future Treatment Trends

7. Global Cluster Headache Treatment Landscape Report Size & Forecast

  • 7.1 Global Market Size Analysis
  • 7.2 Global Market Forecast
  • 7.3 Market Forecast by Treatment Type
  • 7.4 Market Forecast by Route of Administration
  • 7.5 Market Forecast by End User
  • 7.6 Market Forecast by Distribution Channel
  • 7.7 Market Attractiveness Analysis

8. Global Cluster Headache Treatment Landscape Report Segmentation

  • 8.1 By Treatment Type
    • 8.1.1 Acute Treatment
    • 8.1.2 Preventive Treatment
    • 8.1.3 Bridge Treatment
  • 8.2 By Drug Class
    • 8.2.1 Triptans
    • 8.2.2 CGRP Monoclonal Antibodies
    • 8.2.3 Calcium Channel Blockers
    • 8.2.4 Corticosteroids
    • 8.2.5 Other Drug Classes
  • 8.3 By Indication
    • 8.3.1 Episodic Cluster Headache
    • 8.3.2 Chronic Cluster Headache
  • 8.4 By Route of Administration
    • 8.4.1 Oral
    • 8.4.2 Injectable
    • 8.4.3 Intranasal
  • 8.5 By End User
    • 8.5.1 Hospitals
    • 8.5.2 Speciality Clinics
    • 8.5.3 Home Care Settings
  • 8.6 By Distribution Channel
    • 8.6.1 Hospital Pharmacies
    • 8.6.2 Retail Pharmacies
    • 8.6.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

  • 9.1 North America
    • 9.1.1 Market Size & Growth
    • 9.1.2 Demand Drivers
    • 9.1.3 Regulatory Overview
    • 9.1.4 Competitive Intensity
  • 9.2 Europe
    • 9.2.1 Market Size & Growth
    • 9.2.2 Demand Drivers
    • 9.2.3 Regulatory Overview
    • 9.2.4 Competitive Intensity
  • 9.3 Asia-Pacific
    • 9.3.1 Market Size & Growth
    • 9.3.2 Demand Drivers
    • 9.3.3 Regulatory Overview
    • 9.3.4 Competitive Intensity
  • 9.4 Latin America
    • 9.4.1 Market Size & Growth
    • 9.4.2 Demand Drivers
    • 9.4.3 Regulatory Overview
    • 9.4.4 Competitive Intensity
  • 9.5 Middle East & Africa
    • 9.5.1 Market Size & Growth
    • 9.5.2 Demand Drivers
    • 9.5.3 Regulatory Overview
    • 9.5.4 Competitive Intensity

10. Key Countries Analysis

  • 10.1 United States
  • 10.2 Canada
  • 10.3 Germany
  • 10.4 United Kingdom
  • 10.5 France
  • 10.6 Italy
  • 10.7 Spain
  • 10.8 China
  • 10.9 Japan
  • 10.10 India
  • 10.11 South Korea
  • 10.12 Australia
  • 10.13 Brazil
  • 10.14 Mexico
  • 10.15 Saudi Arabia
  • 10.16 South Africa

11. Regulatory & Policy Landscape

  • 11.1 Global Regulatory Overview
  • 11.2 United States Regulatory Framework (FDA)
  • 11.3 European Regulatory Framework (EMA)
  • 11.4 Japan Regulatory Framework (PMDA)
  • 11.5 India Regulatory Framework (CDSCO)
  • 11.6 China Regulatory Framework (NMPA)
  • 11.7 Drug Approval Pathways
  • 11.8 Medical Device Approval Pathways
  • 11.9 Reimbursement and Market Access Policies
  • 11.10 Emerging Regulatory Trends

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Competitive Benchmarking
  • 12.3 Product Portfolio Analysis
  • 12.4 Pipeline Competitiveness
  • 12.5 Strategic Collaborations and Partnerships
  • 12.6 Licensing Agreements
  • 12.7 Mergers and Acquisitions
  • 12.8 Recent Developments

13. Company Profiles

  • 13.1 Eli Lilly and Company
    • 13.1.1 Company Overview
    • 13.1.2 Approved Products for Cluster Headache and Related Neurology Indications
    • 13.1.3 Key Indications
    • 13.1.4 Pipeline Portfolio (Phase I/II/III)
    • 13.1.5 Recent Developments
    • 13.1.6 Strategic Outlook
  • 13.2 electroCore, Inc.
    • 13.2.1 Company Overview
    • 13.2.2 Approved Products and Devices
    • 13.2.3 Key Indications
    • 13.2.4 Pipeline Portfolio
    • 13.2.5 Recent Developments
    • 13.2.6 Strategic Outlook
  • 13.3 Pfizer Inc.
    • 13.3.1 Company Overview
    • 13.3.2 Approved Products
    • 13.3.3 Key Indications
    • 13.3.4 Pipeline Portfolio
    • 13.3.5 Recent Developments
    • 13.3.6 Strategic Outlook
  • 13.4 GlaxoSmithKline plc
    • 13.4.1 Company Overview
    • 13.4.2 Approved Products
    • 13.4.3 Key Indications
    • 13.4.4 Pipeline Portfolio
    • 13.4.5 Recent Developments
    • 13.4.6 Strategic Outlook
  • 13.5 Medtronic
    • 13.5.1 Company Overview
    • 13.5.2 Approved Devices
    • 13.5.3 Key Indications
    • 13.5.4 Pipeline Portfolio
    • 13.5.5 Recent Developments
    • 13.5.6 Strategic Outlook
  • 13.6 Grunenthal GmbH
    • 13.6.1 Company Overview
    • 13.6.2 Approved Products
    • 13.6.3 Key Indications
    • 13.6.4 Pipeline Portfolio
    • 13.6.5 Recent Developments
    • 13.6.6 Strategic Outlook
  • 13.7 Zosano Pharma Corp.
    • 13.7.1 Company Overview
    • 13.7.2 Approved Products
    • 13.7.3 Key Indications
    • 13.7.4 Pipeline Portfolio
    • 13.7.5 Recent Developments
    • 13.7.6 Strategic Outlook
  • 13.8 Bausch Health Companies Inc.
    • 13.8.1 Company Overview
    • 13.8.2 Approved Products
    • 13.8.3 Key Indications
    • 13.8.4 Pipeline Portfolio
    • 13.8.5 Recent Developments
    • 13.8.6 Strategic Outlook
  • 13.9 Viatris Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Approved Products
    • 13.9.3 Key Indications
    • 13.9.4 Pipeline Portfolio
    • 13.9.5 Recent Developments
    • 13.9.6 Strategic Outlook
  • 13.10 Autonomic Technologies Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Approved Products and Devices
    • 13.10.3 Key Indications
    • 13.10.4 Pipeline Portfolio
    • 13.10.5 Recent Developments
    • 13.10.6 Strategic Outlook

14. Future Outlook

  • 14.1 Future Market Trends
  • 14.2 Emerging Technologies
  • 14.3 Pipeline Commercialization Outlook
  • 14.4 Competitive Evolution
  • 14.5 Investment Opportunities
  • 14.6 Scenario Analysis
  • 14.7 Long-Term Market Forecast

15. Methodology

  • 15.1 Research Objectives
  • 15.2 Research Design
  • 15.3 Secondary Research Sources
  • 15.4 Primary Research Methodology
  • 15.5 Market Size Estimation
  • 15.6 Forecasting Methodology
  • 15.7 Data Validation and Triangulation
  • 15.8 Assumptions and Limitations
  • 15.9 Abbreviations and Definitions